Compare Applovin Corporation (APP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applovin Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Applovin Corporation trades at $506 (market cap $170.31B), while Zimmer Biomet Holdings Inc trades at $91.8 (market cap $17.67B). The key difference: Applovin Corporation is far larger — about 9.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| APP | ZBH | |
|---|---|---|
Market Cap | $170.31B | $17.67B |
Sector | Technology | Health |
52-Week High | $733.60 | $107.71 |
52-Week Low | $335.10 | $79.58 |
Enterprise Value | $171.07B | $24.72B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
Zimmer Biomet (ZBH) trades at $91.34, up 2.36% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong profitability with a 70.03% gross margin and has beaten earnings estimates for three consecutive quarters. Recent developments include a $140M acquisition and plans to hire 500 employees in India, signaling growth initiatives.
Outlook is cautiously optimistic with a consensus price target of $98.00, though rising debt levels and competitive pressures pose risks. The stock offers steady dividend income and share repurchases, but investors should weigh execution risks against solid cash flow generation and market positioning in medical devices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
